Try our Advanced Search for more refined results

SANOFI-AVENTIS U.S. LLC et al v. SANDOZ, INC.

  1. September 16, 2011

    Sun Can't Sell Generic Eloxatin Until 2012: Judge

    Sun Pharmaceutical Industries Ltd. can't market its generic version of Sanofi-Aventis SA's colorectal cancer treatment Eloxatin until August 2012, based on the terms of a licensing agreement between the companies, a New Jersey federal judge said Thursday.

  2. February 11, 2011

    Sun Pharma Freezes Generic Eloxatin Sales

    Sun Pharmaceutical Industries Inc. has agreed to temporarily halt its sales of oxaliplatin, the active ingredient in Sanofi-Aventis US LLC's colon cancer drug Eloxatin, as the parties decide how to proceed with their revived patent infringement dispute.

  3. March 19, 2010

    Sanofi, Dabur Patent Dispute Over Eloxatin Survives

    A federal judge has denied opposing summary judgment motions for plaintiff Sanofi-Aventis US LLC and defendants Fresenius Kabi Oncology PLC and Dabur Pharma Ltd. in an infringement suit over two patents related to the popular colon cancer drug Eloxatin.

  4. March 15, 2010

    Fresenius Infringes Sanofi's Eloxatin Patent: Judge

    Sanofi-Aventis US LLC has won summary judgment of infringement against Fresenius Kabi Pharma Ltd., scoring a victory in its bid to keep generic versions of popular colon cancer drug Eloxatin off the market.

  5. March 10, 2010

    Sanofi Loses Injunction Bid In Generic Eloxatin Spat

    A federal judge has again denied Sanofi-Aventis US LLC's request for a preliminary injunction against Fresenius Kabi Pharma Ltd., one of the last remaining defendants in the pharmaceutical giant's battle to keep generic versions of popular colon cancer drug Eloxatin off the market.

  6. March 02, 2010

    Sanofi Loses Last-Ditch Bid To Upend Eloxatin Deal

    A federal judge has deemed enforceable a deal that Sanofi-Aventis U.S. LLC reached with Sun Pharmaceutical Industries Ltd. ending a patent fight over generic versions of Sanofi's colon cancer drug Eloxatin, rejecting Sanofi's second attempt to undo the deal.

  7. October 06, 2009

    Sanofi-Sun Settlement In Eloxatin Suit Ruled Valid

    A judge has ruled that Sanofi-Aventis is bound to a settlement agreement it reached with Sun Pharmaceutical Industries Ltd. in a patent infringement suit over generic versions of Sanofi’s popular colon cancer drug Eloxatin, even though it failed to sign the agreement.

  8. July 06, 2009

    Sanofi Loses Bid To Stay Launch Of Generic Eloxatin

    A judge has denied Sanofi-Aventis US LLC's request to stay the launch of generic versions of its popular colon cancer drug Eloxatin pending appeal of a finding of noninfringement in Sanofi's suit against Sandoz Inc., Teva Pharmaceutical Industries Ltd. and others.

  9. June 18, 2009

    Generics Triumph Over Sanofi In Cancer Drug Quarrel

    Sandoz Inc., Mayne Pharma Inc., Teva Pharmaceutical Industries Ltd. and Hospira Inc. have won summary judgment in a dispute with Sanofi-Aventis US LLC, which accused the generics manufacturers of infringing two patents for the popular colon cancer drug Eloxatin.

  10. June 15, 2007

    Sanofi Fights To Hang On To Eloxatin

    In a move to defend its claim to the U.S. market, Sanofi-Aventis U.S. LLC sued Sandoz Inc. Thursday for allegedly infringing a patent for its popular colon cancer drug, which a handful of other countries have already rejected.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!